Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RNN798
- Development stage
- Preclinical
- Lead developer
- Rona Therapeutics
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
RNN798 is a preclinical-stage small interfering RNA (siRNA) therapeutic candidate being developed by Shanghai Rona Therapeutics. It is built upon the company's proprietary GAIA platform, which is a liver-targeting delivery technology designed to achieve potent and durable gene silencing through chemical modifications and specific ligands. While the specific molecular target and primary therapeutic indication for RNN798 have not been publicly disclosed by the developer, the GAIA platform generally focuses on addressing unmet needs in metabolic, cardiovascular, and renal diseases by modulating gene expression in the liver.
Beyond the preview
Go deeper on RNN798.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RNN798.